Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

Findings may guide decisions about which patients will benefit most from treatment with sorafenib

  • Advanced hepatocellular carcinoma (HCC) is commonly treated with sorafenib
  • Subset of CD8+ cells are biomarker linked with survival benefit, team shows
  • Evidence could lead to more individualized treatments for liver cancer patients
     

BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to a common chemotherapy treatment for liver cancer. They hope that their analysis of immune responses among patients receiving sorafenib can lead to more individualized treatment options and better overall outcomes for patients diagnosed with the disease.

thanavala_for_web.jpg?itok=qifvCwI_

Dr. Yasmin Thanavala and team found that elevated levels of a subset of cytotoxic CD8+ T cells were a good biomarker of survival for patients taking sorafenib for liver cancer.

The 4-year study, led by Department of Immunology scientist Yasmin Thanavala, PhD, was published online this week in JCI Insight, a peer-reviewed journal published by the American Society for Clinical Investigation, and also to be highlighted in the journal’s JCI This Month digest for September 2019.

Hepatocellular carcinoma (HCC), which can arise from liver cirrhosis, is the most common form of liver cancer. The mainstay oral chemotherapy treatment for patients with advanced HCC is sorafenib — but side effects from this drug may cause many patients to miss doses or discontinue treatment.

The researchers, who included Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park, collected blood samples from 30 patients both before treatment and at two timepoints during treatment with sorafenib. They observed elevated levels of a subset of CD8+ cytotoxic T-cells (CD8+ Ki67+ T cells producing IFN?? producing interferon type II, an important immune protein that destroys tumor cells and significantly reduces risk of death over time. Similarly, CD8+ cells showed an increase in granzyme B, an important enzyme that helps drive cell death.

Additional findings showed that patients with a high ratio of CD4+ T-effector/T-regulatory cells prior to treatment showed significant improvement in both progression-free and overall survival. Decreased numbers of two important immune checkpoint proteins expressed on T-cells — PD-1 and CTLA-1 — suggests that a combination treatment of sorafenib with checkpoint inhibitors such as nivolumab and pembrolizumab could produce positive results in the future.

“Studying biomarkers that correlate with progression-free or overall survival can help reduce exposure to therapies that have an impact on a patient’s quality of life and survival,” says Dr. Thanavala, who led this research. “Utilizing this information, our evidence supports the rationale that patients could benefit from a regimen of sorafenib and immunotherapy, which could help with antitumor immunity and improve the magnitude and strength of antitumor responses.”

The study, “Augmentation of IFN-y+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy,” is available at insight.jci.org. This work was supported by the National Cancer Institute, or NCI (grant P30CA016056), the National Comprehensive Cancer Network® (NCCN®) Oncology Research Program from general research support provided by Bayer U.S LLC (NCCNSORA0002), and by donations to Roswell Park.

###

For an online version of this release, please visit: https://www.roswellpark.org/media/news/roswell-park-researchers-identify-immune-biomarker-response-patients-advanced-liver

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

 



If you would rather not receive future communications from Roswell Park Comprehensive Cancer Center, let us know by clicking here.
Roswell Park Comprehensive Cancer Center, Elm And Carlton St, Buffalo, NY 14263-0001 United States
Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

Annual-Meeting

2 months
68 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Up Next Autoplay
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
Category: Acute Lymphoblastic Leukemia
31 Views
Stan 1 month
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
Category: Acute Lymphoblastic Leukemia
18 Views
Cancer-News 1 month
IASLC World Conference on Lung Cancer—Press Briefing Summary from Sunday, September 8th in Barcelona
IASLC World Conference on Lung Cancer—Press Briefing Summary from Sunday, September 8th in Barcelona
Category: Acute Lymphoblastic Leukemia
29 Views
Cancer-News 1 month
IPS based approach for treating virus-induced tumors
IPS based approach for treating virus-induced tumors
Category: Acute Lymphoblastic Leukemia
9 Views
Cancer-News 1 month
Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Category: Acute Lymphoblastic Leukemia
39 Views
Cancer-News 1 month
AMGEN ANNOUNCES NEW CLINICAL DATA EVALUATING NOVEL INVESTIGATIONAL KRASG12C INHIBITOR IN LARGER  PATIENT GROUP AT WCLC 2019
AMGEN ANNOUNCES NEW CLINICAL DATA EVALUATING NOVEL INVESTIGATIONAL KRASG12C INHIBITOR IN LARGER PATIENT GROUP AT WCLC 2019
Category: Acute Lymphoblastic Leukemia
24 Views
Cancer-News 1 month
Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
Category: Acute Lymphoblastic Leukemia
13 Views
Cancer-News 1 month
Intraoperative Teamwork of Breast Cancer Surgeon and Pathologist Greatly Reduces Need for Second Surgery After Lumpectomy
Intraoperative Teamwork of Breast Cancer Surgeon and Pathologist Greatly Reduces Need for Second Surgery After Lumpectomy
Category: Acute Lymphoblastic Leukemia
23 Views
Cancer-News 1 month
Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging
Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging
Category: Acute Lymphoblastic Leukemia
24 Views
Cancer-News 1 month
Will advances in AI lead to more effective screening practices for ovarian cancer?
Will advances in AI lead to more effective screening practices for ovarian cancer?
Category: Acute Lymphoblastic Leukemia
21 Views
Cancer-News 1 month